#Clinical Trials

🏢Release 📈 Stocks

Phanes Therapeutics Advances Peluntamig for Neuroendocrine Prostate Cancer

October 15, 2026 (9 days ago)

Phanes Therapeutics accelerates the clinical development of Peluntamig (PT217), targeting the growing demand for specialized therapies in the treatment-resistant neuroendocrine prostate cancer…

PHANES

🌍 GLOBAL Read More →

🏢Release 📈 Stocks — 📊 Neutral

SCRS Launches Intelligence Platform to Accelerate Clinical Site Engagement

October 15, 2026 (9 days ago)

SCRS introduces a new intelligence platform to help pharmaceutical sponsors and CROs identify operational gaps and improve clinical site engagement efficiency.

🌍 AMERICAS Read More →

🏢Release 📈 Stocks

Bold Therapeutics Hits 60-Patient Enrollment Milestone in Phase 2 Cancer Trial

October 15, 2026 (9 days ago)

Bold Therapeutics reaches the 60-patient enrollment midpoint in its Phase 2 trial for BOLD-100, advancing its clinical development pipeline for novel metallotherapeutics.

Bold Therapeutics

🌍 AMERICAS Read More →

🏢Release 📈 Stocks

Actinium Pharmaceuticals Advances ATNM-400 Prostate Cancer Trial

October 15, 2026 (9 days ago)

Actinium Pharmaceuticals moves forward with its Phase 1 trial for ATNM-400, a novel non-PSMA targeted alpha therapy designed to treat metastatic castration-resistant…

ATNM

🌍 AMERICAS Read More →

🏢Release 📈 Stocks — 📊 Neutral

New Funding Advances Long-Acting Subcutaneous HIV Prevention Implant

October 15, 2026 (9 days ago)

New funding accelerates the development of a long-acting subcutaneous HIV prevention implant, moving the technology toward IND filing and initial human clinical…

🌍 AMERICAS Read More →

🏢Release 📈 Stocks

AbbVie Shares Gain as SKYRIZI Hits Primary Endpoints in Crohn's Study

October 13, 2026 (11 days ago)

AbbVie's SKYRIZI achieves significant endoscopic remission in Phase 3 Crohn's disease trials, bolstering the company's immunology portfolio and growth outlook.

ABBV

🌍 AMERICAS Read More →

🏢Release 📈 Stocks

Suvoda Launches Sofia AI Assistant to Streamline Clinical Trial Operations

October 13, 2026 (11 days ago)

Suvoda introduces Sofia, a specialized AI assistant engineered to navigate the regulatory complexities and data-heavy requirements of modern clinical trial management.

Suvoda

🌍 AMERICAS Read More →

🏢Release 📈 Stocks

MetaVia Appoints Sarah Browne as Chief Medical Officer to Lead Drug Pipeline

October 13, 2026 (11 days ago)

MetaVia Inc. strengthens its leadership team with the appointment of Sarah Browne as Chief Medical Officer to accelerate the development of its…

MTVA

🌍 AMERICAS Read More →

🏢Release 📈 Stocks — 📊 Neutral

Evergreen Therapeutics Secures FDA Fast Track Designation for AI Pipeline

October 13, 2026 (11 days ago)

Evergreen Therapeutics receives FDA Fast Track status, marking a significant regulatory milestone for its AI-driven clinical development program aimed at addressing complex…

🌍 AMERICAS Read More →

🏢Release 📈 Stocks

TRI Launches TRIAL.OS to Advance AI-Augmented Clinical Trial Operations

October 13, 2026 (11 days ago)

TRI introduces TRIAL.OS, a new AI-driven operating system aimed at optimizing clinical research workflows and elevating standards in risk-based quality management.

TRI

🌍 EUROPE Read More →

🏢Release 📈 Stocks

Johnson & Johnson TREMFYA Hits 94% Remission Rate in Crohn's Disease Study

October 12, 2026 (12 days ago)

Johnson & Johnson's TREMFYA demonstrates strong efficacy in Crohn's disease trials, with 94% clinical remission and 61% endoscopic remission, bolstering the company's…

JNJ

🌍 AMERICAS Read More →

🏢Release 📈 Stocks

Johnson & Johnson Shares Gain as TREMFYA Shows Crohn's Disease Efficacy

October 12, 2026 (12 days ago)

Johnson & Johnson's TREMFYA shows consistent perianal fistula remission in Crohn's disease patients, bolstering the company's pharmaceutical outlook.

JNJ

🌍 AMERICAS Read More →